非小细胞肺癌的联合免疫治疗现状

对于晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）的患者来说，化疗、放疗、靶向治疗及抗血管生成治疗虽然可以改善其预后，但经相关研究发现，NSCLC患者的5年生存率仍不尽人意。近年来以程序性死亡蛋白1（programmed cell death protein 1,PD-1）/程序性死亡蛋白配体1（programmed death-ligand 1，PD-L1）抑制剂为代表免疫检查点抑制剂的出现为晚期NSCLC患者的治疗带来了新的希望。探索免疫检查点抑制剂联合化疗、抗血管生成药物、放疗的各项治疗策略是目前肿瘤界的热门话题，本文将对NSCLC联合免疫治疗的现状进行总结与讨论。

Current status of combined immunotherapy for non-small cell lung cancer

For patients with advanced non-small cell lung cancer (NSCLC),chemotherapy,radiotherapy,targeted therapy and anti-angiogenesis therapy can improve their prognosis,but the 5-year survival rate of NSCLC patients is still unsatisfactory.In recent years,the emergence of programmed cell death protein 1 (PD1)/programmed death ligand 1 (PD-L1) inhibitors as the representative of immunological checkpoint inhibitors has brought new hope for advanced NSCLC patients.Exploring the strategies of immuno-checkpoint inhibitors combined with chemotherapy,anti-angiogenesis drugs and radiotherapy is a hot topic in the field of cancer at present.This review will summarize and discuss the current situation of NSCLC combined with immunotherapy.